Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737

Jing Wang

School of Nursing

Press/Media: Press / Media

Period	Nov 29 2018 → Nov 30 2018

Media coverage

Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet	Canadian Life Sciences Database
Country	Switzerland
Date	11/30/18
Persons	Jing Wang

Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet Biotechgate
Country Switzerland
Date 11/30/18
Persons Jing Wang
Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet BioSpace
Country United States
Date 11/30/18
Persons Jing Wang
Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet PipelineReview
Country Spain
Date 11/30/18
Persons Jing Wang
Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet Canada NewsWire
Country Canada
Date 11/29/18
Persons Jing Wang
Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet PR Newswire
Country United States
Date 11/29/18
Persons Jing Wang
Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet Canada NewsWire
Country Canada
Date 11/29/18
Persons Jing Wang
Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet PR Newswire
Country United States
Date 11/29/18
Persons Jing Wang
Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet Canada NewsWire
Country Canada
Date 11/29/18
Persons Jing Wang
Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet PR Newswire
Country United States
Date 11/29/18
Persons Jing Wang
Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet Nasdaq
Country United States
Date 11/29/18
Persons Jing Wang
Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet India Pharma News
Country India
Date 11/29/18
Persons Jing Wang
Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet TickerTech.com
Country United States
Date 11/29/18
Persons Jing Wang
Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet Stockwatch
Country Canada
Date 11/29/18
Persons Jing Wang
Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet PharmiWeb
Country United Kingdom
Date 11/29/18
Persons Jing Wang
Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet Finanzen.ch
Country Switzerland
Date 11/29/18
Persons Jing Wang
Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet Markets Business Insider
Country United States
Date 11/29/18
Persons Jing Wang
Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet Spoke.com
Country United States
Date 11/29/18
Persons Jing Wang
Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Media name/outlet Central Charts
Country France
Date 11/29/18
Persons Jing Wang

View all 19

View less